作者: Bijay Singh , Samir Mitragotri
DOI: 10.1016/J.BIOTECHADV.2019.01.006
关键词:
摘要: Clinical translation of nanoparticle drug (nanodrug) delivery systems for cancer therapy is primarily hindered by short half-life nanodrugs in blood circulation and their poor ability tumor targeting penetration vivo. Circulatory cells have garnered much attention as vehicles due to biocompatibility, high mobility, biodegradability, tissue capability, loading capacity, cross biological barriers inherent remain long enough accumulate within the tumors. Here, we review progress potential circulatory nanodrug vehicles, especially therapy.